Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
DOI:
https://doi.org/10.2340/actadv.v104.34375Keywords:
Lebrikizumab, Moderate-to-severe AD, Japanese patients, Patient-reported outcomesAbstract
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low- to mid-potency topical corticosteroids on patient-reported outcomes at 16 weeks in Japanese patients with moderate-to-severe atopic dermatitis is evaluated. Eligible patients (n = 286) were randomized 2:2:3 to receive placebo+ topical corticosteroids, 250 mg lebrikizumab every 4 weeks (LEBQ4W+topical corticosteroids, 500 mg loading dose at baseline), or 250 mg lebrikizumab every 2 weeks (LEBQ2W+ topical corticosteroids, 500 mg loading dose at baseline and Week 2) by subcutaneous injection. All PRO endpoints for the study were met; patients in the lebrikizumab in combination with topical corticosteroids groups demonstrated statistically significant and clinically meaningful improvements compared with placebo in combination with topical corticosteroids in Skin Pain NRS, DLQI, POEM, WPAI-AD, and SCORAD scales. Lebrikizumab combined with topical corticosteroids compared with placebo+topical corticosteroids improved patient-reported outcomes in Japanese patients with moderate-to-severe atopic dermatitis.
Downloads
References
Tanaka T, et al. Prevalence of dermatological disorders in Japan: a nationwide, cross-sectional, seasonal, multicenter, hospital-based study. J Dermatol 2011; 38: 310-320.
https://doi.org/10.1111/j.1346-8138.2011.01209.x
Katoh N, Saeki H, Kataoka Y, Etoh T, Teramukai S, Takagi H, et al. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): baseline characteristics, treatment history and disease burden. J Dermatol 2019; 46: 290-300.
https://doi.org/10.1111/1346-8138.14787
Saeki H, Iizuka H, Mori Y, Akasaka T, Takagi H, Kitajima Y, et al. Prevalence of atopic dermatitis in Japanese elementary schoolchildren. Br J Dermatol 2005; 152: 110-114.
https://doi.org/10.1111/j.1365-2133.2004.06271.x
Saeki H, Tsunemi Y, Fujita H, Kagami S, Sasaki K, Ohmatsu H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults. J Dermatol 2006; 33: 817-819.
https://doi.org/10.1111/j.1346-8138.2006.00187.x
Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 2017; 119: 548-552.
https://doi.org/10.1016/j.anai.2017.09.076
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol 2018; 121: 340-347.
https://doi.org/10.1016/j.anai.2018.07.006
Chrostowska-Plak D, Reich A, Szepietowski JC. Relationship between itch and psychological status of patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2013; 27: e239-e242.
https://doi.org/10.1111/j.1468-3083.2012.04578.x
Yano C, Saeki H, Ishiji T, Ishiuji Y, Sato J, Tofuku Y, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol 2013; 40: 736-739.
https://doi.org/10.1111/1346-8138.12220
Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis. Ann Allergy Asthma Immunol 2021; 126: 21-31.
https://doi.org/10.1016/j.anai.2020.08.016
Dhadwal G, Albrecht L, Gniadecki R, Poulin Y, Yeung J, Hong C-h, et al. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section IV: treatment options for the management of atopic dermatitis. J Cutan Med Surg 2018; 22: 21S-29S.
https://doi.org/10.1177/1203475418805721
Kamei K, Hirose T, Yoshii N, Tanaka A. Burden of illness, medication adherence, and unmet medical needs in Japanese patients with atopic dermatitis: a retrospective analysis of a cross-sectional questionnaire survey. J Dermatol 2021; 48: 1491-1498.
https://doi.org/10.1111/1346-8138.16054
Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc 2019; 40: 84-92.
https://doi.org/10.2500/aap.2019.40.4202
Tsoi LC, Rodriguez E, Degenhardt F, Baurecht H, Wehkamp U, Volks N, et al. Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis. J Invest Dermatol 2019; 139: 1480-1489.
https://doi.org/10.1016/j.jid.2018.12.018
Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy 2020; 75: 54-62.
https://doi.org/10.1111/all.13954
Szegedi K, Lutter R, Bos JD, Luiten RM, Kezic S, Middelkamp-Hup MA. Cytokine profiles in interstitial fluid from chronic atopic dermatitis skin. J Eur Acad Dermatol Venereol 2015; 29: 2136-2144.
https://doi.org/10.1111/jdv.13160
Okragly A, Ryuzoji A, Daniels M, Patel C, Benschop R. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. 4th Inflammatory Skin Disease Summit, New York, November 3-6, 2021. Exp Dermatol 2021; 30: 3-43.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388: 1080-1091.
https://doi.org/10.1056/NEJMoa2206714
Simpson EL, Gooderham M, Wollenberg A, Weidinger S, Armstrong A, Soung J, et al. Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere). JAMA Dermatol 2023; 159: 182-191.
https://doi.org/10.1001/jamadermatol.2022.5534
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol 2014; 71: 116-132.
https://doi.org/10.1016/j.jaad.2014.03.023
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol 2001; 10: 11-18.
https://doi.org/10.1034/j.1600-0625.2001.100102.x
Simpson E, Bissonnette R, Eichenfield LF, Guttman-Yassky E, King B, Silverberg JI, et al. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol 2020; 83: 839-846.
https://doi.org/10.1016/j.jaad.2020.04.104
Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, et al. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes 2021; 19: 247.
https://doi.org/10.1186/s12955-021-01877-8
Basra MKA, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Dermatology 2015; 230: 27-33.
https://doi.org/10.1159/000365390
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
https://doi.org/10.1111/bjd.12590
Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-365.
https://doi.org/10.2165/00019053-199304050-00006
Torisu-Itakura H, Anderson P, Piercy J, Pike J, Sakamoto A, Kabashima K. Impact of itch and skin pain on quality of life in adult patients with atopic dermatitis in Japan: results from a real-world, point-in-time, survey of physicians and patients. Curr Med Res Opin 2022; 38: 1401-1410.
https://doi.org/10.1080/03007995.2022.2092352
Schram ME, Spuls PI, Leeflang MMG, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy 2012; 67: 99-106.
https://doi.org/10.1111/j.1398-9995.2011.02719.x
Legat FJ. Itch in atopic dermatitis: what is new? Front Med 2021; 8: 644760.
https://doi.org/10.3389/fmed.2021.644760
Murota H, Koike Y, Ishii K, Calimlim BM, Ludwikowska M, Toumi M, et al. Evaluating the burden of pruritus due to atopic dermatitis in Japan by patient-reported outcomes. J Med Econ 2021; 24: 1280-1289.
https://doi.org/10.1080/13696998.2021.2002559
Elmariah SB. Adjunctive management of itch in atopic dermatitis. Dermatol Clin 2017; 35: 373-394.
https://doi.org/10.1016/j.det.2017.02.011
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol 2021; 184: 304-309.
https://doi.org/10.1111/bjd.19580
Yosipovitch G. Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: results from two phase 3 trials in patients with moderate-to-severe atopic dermatitis. American Academy of Dermatology - 81st Annual Meeting 2023
https://doi.org/10.1016/j.jaad.2023.07.246
Yosipovitch G. Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of 2 phase 3 randomized controlled trials. American Academy of Dermatology - 81st Annual Meeting 2023. https://doi.org/10.26226/m.649c5e4156241620f7b6a64c
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract 2019; 7: 2699-2706.
https://doi.org/10.1016/j.jaip.2019.05.055
Maarouf M, Kromenacker B, Capozza KL, Kempton D, Hendricks A, Tran K, et al. Pain and itch are dual burdens in atopic dermatitis. Dermatitis 2018; 29: 278-281.
https://doi.org/10.1097/DER.0000000000000406
Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain 2003; 4: 407-414.
https://doi.org/10.1016/S1526-5900(03)00716-8
Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, et al. Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement. Br J Dermatol 2017; 176: 979-984.
https://doi.org/10.1111/bjd.15179
Silverberg JI, Lei D, Yousaf M, Janmohamed SR, Vakharia PP, Chopra R, et al. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study. Br J Dermatol 2021; 184: 888-895.
Published
How to Cite
License
Copyright (c) 2024 Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
